Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: plaque psoriasis

Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  August 7, 2020

In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:mirikizumabplaque psoriasissecukinumab

Apremilast Promising for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2020

Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…

Filed under:AnalgesicsDrug Updates Tagged with:apremilastplaque psoriasisskin

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 5, 2020

In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…

Filed under:Drug Updates Tagged with:plaque psoriasisrisankizumabsecukinumab

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  May 14, 2019

In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:CanadaFDAmeloxicamnon-opioid pain shotPainplaque psoriasisrizankixumabU.S. Food and Drug Administration (FDA)

Mirikizumab Promising for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  April 10, 2019

During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…

Filed under:Biologics/DMARDsDrug Updates Tagged with:mirikizumabplaque psoriasisskin

FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

Michele B. Kaufman, PharmD, BCGP  |  December 3, 2018

The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…

Filed under:Drug Updates Tagged with:dermatitisdupilumabFDAhalobetasol propionate lotionplaque psoriasisU.S. Food and Drug Administration (FDA)

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

Michele B. Kaufman, PharmD, BCGP  |  October 22, 2018

According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-adbmBMS-986165plaque psoriasisTYK2 inhibitortyrosine kinase 2 inhibitor

FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  July 9, 2018

The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…

Filed under:AnalgesicsDrug Updates Tagged with:ConsensiDuobriiFDA approvalhypertensionosteoarthritis (OA)PainPain ManagementU.S. Food and Drug Administration (FDA)

Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 18, 2018

On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…

Filed under:Drug Updates Tagged with:Certolizumab PegolFDAFDA approvalplaque psoriasisPsoriasisU.S. Food and Drug Administration (FDA)

Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  November 3, 2017

In October, the FDA approved ustekinumab to treat patients 12 years or older who have moderate to severe plaque psoriasis…

Filed under:Drug Updates Tagged with:AdolescentsFDAplaque psoriasisPsoriasisU.S. Food and Drug Administration (FDA)ustekinumab

  • 1
  • 2
  • 3
  • …
  • 20
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences